Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.

FEBS letters - 1 Sept 2021

Padhi Aditya K, Dandapat Jagneshwar, Saudagar Prakash, Uversky Vladimir N, Tripathi Timir

Abstract excerpt

Favipiravir is a broad-spectrum inhibitor of viral RNA-dependent RNA polymerase (RdRp) currently being used to manage COVID-19. Accumulation of mutations in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RdRp may facilitate antigenic drift, generating favipiravir resistance. Focussing on the chain-termination mechanism utilized by favipiravir, we used high-throughput interface-based protein design...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Point Mutation

Share to Pyrazines

Share to RNA-Dependent RNA Polymerase

Share to RNA, Viral

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34409597
DOI: 10.1002/1873-3468.14182
PMCID: PMC8426738

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.PMID 34409597Read ↗

Structural Proteomics-Driven Targeted Design of Favipiravir-Binding Site in The RdRp of SARS-CoV-2 Unravels Susceptible Hotspots and Resistance MutationsSemantic proximity Read ↗

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesisSemantic proximity Read ↗

Rational Design of the Remdesivir Binding Site in the RNA-dependent RNA Polymerase of SARS-CoV-2: Implications for Potential ResistanceSemantic proximity Read ↗

Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.Semantic proximity Read ↗

Structural basis of SARS-CoV-2 polymerase inhibition by FavipiravirSemantic proximity Read ↗

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistanceSemantic proximity Read ↗

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In SilicoSemantic proximity Read ↗

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?Semantic proximity Read ↗

Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug DiscoverySemantic proximity Read ↗

A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens.Semantic proximity Read ↗

Discovery of Nirmatrelvir Resistance Mutations in SARS-CoV-2 3CLpro: A Computational-Experimental Approach.Semantic proximity Read ↗

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.